Compare Harmony Gold Mining Co. (HMY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Regeneron Pharmaceuticals Inc — how do they compare? Harmony Gold Mining Co. trades at $19.99 (market cap $12.24B), while Regeneron Pharmaceuticals Inc trades at $795.64 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.7× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| HMY | REGN | |
|---|---|---|
Market Cap | $12.24B | $82.06B |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $812.27 |
52-Week Low | $12.61 | $555.51 |
Enterprise Value | $12.58B | $76.77B |
Dividend Yield | 2.09% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $19.90, up 0.96% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with 2024 revenue of $61.38B and net income of $8.59B, achieving a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but strong operational cash flow growth to $15.65B in 2024. The stock's valuation remains reasonable with P/E of 12.26 and EV/EBITDA of 6.41, while the company transitions toward gold-copper diversification.
HMY presents a compelling value proposition with attractive profitability metrics and strategic diversification, though analyst sentiment remains cautious with 70% hold ratings. Key risks include gold price volatility and execution challenges in copper expansion. The stock trades near resistance at $20-21 with overbought RSI signals suggesting potential near-term consolidation before further upside.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
